NR enters cells via equilibrative nucleoside transporters (ENTs), then is phosphorylated by NR kinase (NRK1/2) to NMN, which is then adenylated by NMNAT to produce NAD+. This is one more step than NMN (which skips the NRK phosphorylation). The debate: NMN proponents argue NMN is "one step closer" to NAD+; NR proponents argue NR has better oral bioavailability and more clinical data. In practice, both reliably raise NAD+ in human blood. The gap: raising blood NAD+ does not automatically translate to tissue NAD+ or functional health benefits — which explains why the NIRI trial showed NAD+ up but no metabolic improvement.
No critical interactions identified.
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.